[
  {
    "ts": null,
    "headline": "Why Organon Is A Top Pick For Income Investors",
    "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
    "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742252303,
      "headline": "Why Organon Is A Top Pick For Income Investors",
      "id": 133211092,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472143072/image_1472143072.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
      "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96"
    }
  },
  {
    "ts": null,
    "headline": "Incyte stock dives after drug trial disappoints investors",
    "summary": "Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials. Yahoo Finance Senior Reporter Anjalee Khemlani outlines the details on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=e144f4b7c847b685fe5fecbf3280da86be43023e386bcf1a868eb8ab69064c41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742244770,
      "headline": "Incyte stock dives after drug trial disappoints investors",
      "id": 133327553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials. Yahoo Finance Senior Reporter Anjalee Khemlani outlines the details on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=e144f4b7c847b685fe5fecbf3280da86be43023e386bcf1a868eb8ab69064c41"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
    "summary": "The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.",
    "url": "https://finnhub.io/api/news?id=0da64617c0f8ee249ad2104a4b2c5ecd104076d2f63641bb084df34714bdc42a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742243527,
      "headline": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
      "id": 133327554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.",
      "url": "https://finnhub.io/api/news?id=0da64617c0f8ee249ad2104a4b2c5ecd104076d2f63641bb084df34714bdc42a"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'",
    "summary": "Incyte's skin disease treatment looks \"viable, but not competitive with biologics,\" an analyst said Monday as Incyte stock fell.",
    "url": "https://finnhub.io/api/news?id=1cda9e66c150f3aa4521a8e3b4a077528a9971868c7ba02b27ca9dfbd1ff1db8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742242291,
      "headline": "Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'",
      "id": 133327555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte's skin disease treatment looks \"viable, but not competitive with biologics,\" an analyst said Monday as Incyte stock fell.",
      "url": "https://finnhub.io/api/news?id=1cda9e66c150f3aa4521a8e3b4a077528a9971868c7ba02b27ca9dfbd1ff1db8"
    }
  },
  {
    "ts": null,
    "headline": "Oil pressures, Robinhood, Incyte: Market Minute",
    "summary": "Yahoo Finance host Julie Hyman is tracking some of the biggest stock stories in this Market Minute, including Red Sea tensions pressuring oil prices (CL=F, BZ=F), the launch of Robinhood Markets' (HOOD) prediction markets hub, and Incyte's (INCY) Phase 3 trial data on a skin condition treatment. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=24b043ef8dbcdc5d1b307752eae42d43f2b2981fc43b5229c31dc0459fa96635",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742234964,
      "headline": "Oil pressures, Robinhood, Incyte: Market Minute",
      "id": 133327556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Julie Hyman is tracking some of the biggest stock stories in this Market Minute, including Red Sea tensions pressuring oil prices (CL=F, BZ=F), the launch of Robinhood Markets' (HOOD) prediction markets hub, and Incyte's (INCY) Phase 3 trial data on a skin condition treatment. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=24b043ef8dbcdc5d1b307752eae42d43f2b2981fc43b5229c31dc0459fa96635"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Decliners",
    "summary": "Affirm (AFRM) retreated Monday after CNBC reported retailer Walmart (WMT) plans to select rival Swed",
    "url": "https://finnhub.io/api/news?id=acfc8084b4eaa218a251d26d9217d21709b017ebd7f4b8a38dbd42655ad77b0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742234374,
      "headline": "Top Midday Decliners",
      "id": 133327557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Affirm (AFRM) retreated Monday after CNBC reported retailer Walmart (WMT) plans to select rival Swed",
      "url": "https://finnhub.io/api/news?id=acfc8084b4eaa218a251d26d9217d21709b017ebd7f4b8a38dbd42655ad77b0c"
    }
  },
  {
    "ts": null,
    "headline": "Why Incyte (INCY) Stock Is Nosediving",
    "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.",
    "url": "https://finnhub.io/api/news?id=5d20f1316bf21b4ac52e9c988bed62eb9e51357036661af1a7020275c356e861",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742233926,
      "headline": "Why Incyte (INCY) Stock Is Nosediving",
      "id": 133327558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.",
      "url": "https://finnhub.io/api/news?id=5d20f1316bf21b4ac52e9c988bed62eb9e51357036661af1a7020275c356e861"
    }
  },
  {
    "ts": null,
    "headline": "Incyte stock hit by 11% despite paediatric dermatology trials hitting target",
    "summary": "The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.",
    "url": "https://finnhub.io/api/news?id=24f0ca4a53c0dff82658ea2a8a61099e30796a3bb6568443b68274390ea54e1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742231465,
      "headline": "Incyte stock hit by 11% despite paediatric dermatology trials hitting target",
      "id": 133327559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.",
      "url": "https://finnhub.io/api/news?id=24f0ca4a53c0dff82658ea2a8a61099e30796a3bb6568443b68274390ea54e1a"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=053cd820f2863ad1ea1fea00d42c845f3b9c87247c11a4013ebd44418297fac7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742229000,
      "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "id": 133258357,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=053cd820f2863ad1ea1fea00d42c845f3b9c87247c11a4013ebd44418297fac7"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results",
    "summary": "Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.",
    "url": "https://finnhub.io/api/news?id=492814e5f77b166ee3b6e4b3ced0a9b3d362e46f646472ca8ff0e2e2256f6e7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742227254,
      "headline": "Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results",
      "id": 133327560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.",
      "url": "https://finnhub.io/api/news?id=492814e5f77b166ee3b6e4b3ced0a9b3d362e46f646472ca8ff0e2e2256f6e7a"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
    "summary": "U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.",
    "url": "https://finnhub.io/api/news?id=d5e20e708c810eadc2f47b7986f06b7282e3243847681c6a06d072e894cd5c7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742227236,
      "headline": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
      "id": 133327561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.",
      "url": "https://finnhub.io/api/news?id=d5e20e708c810eadc2f47b7986f06b7282e3243847681c6a06d072e894cd5c7f"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Is Today’s Worst S&P 500 Stock. Here’s Why.",
    "summary": "The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t think it was enough.",
    "url": "https://finnhub.io/api/news?id=7acc97d6f6ab646eddf93e4a59985321dffaca544040a9bfc62abfee53fbd96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742224860,
      "headline": "Incyte Is Today’s Worst S&P 500 Stock. Here’s Why.",
      "id": 133327562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t think it was enough.",
      "url": "https://finnhub.io/api/news?id=7acc97d6f6ab646eddf93e4a59985321dffaca544040a9bfc62abfee53fbd96e"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag",
    "summary": "S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag",
    "url": "https://finnhub.io/api/news?id=405beaf40f6b3d784467d821d3572c56547ec9fab2ecab54513a0a838e38e7b9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742196600,
      "headline": "S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag",
      "id": 133221714,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag",
      "url": "https://finnhub.io/api/news?id=405beaf40f6b3d784467d821d3572c56547ec9fab2ecab54513a0a838e38e7b9"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's skin disease drug meets main goal in two late-stage studies",
    "summary": "Incyte said on Monday itsexperimental drug has met the main goal in two separatelate-stage studies testing it in patients with an inflammatoryskin condition called hidradenitis suppurativa. ...",
    "url": "https://finnhub.io/api/news?id=70068b516dc5b6356c5e75eee1a617a4505d82ab5005e02014bbfed5f9f0c6ae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742196183,
      "headline": "Incyte's skin disease drug meets main goal in two late-stage studies",
      "id": 133206265,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte said on Monday itsexperimental drug has met the main goal in two separatelate-stage studies testing it in patients with an inflammatoryskin condition called hidradenitis suppurativa. ...",
      "url": "https://finnhub.io/api/news?id=70068b516dc5b6356c5e75eee1a617a4505d82ab5005e02014bbfed5f9f0c6ae"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa",
    "summary": "Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa",
    "url": "https://finnhub.io/api/news?id=3f8a87168e18ae22c0fd3c0ed527d12ddb1df4bd78260ecceb5fe40021af6d00",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742196060,
      "headline": "Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa",
      "id": 133258360,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa",
      "url": "https://finnhub.io/api/news?id=3f8a87168e18ae22c0fd3c0ed527d12ddb1df4bd78260ecceb5fe40021af6d00"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa",
    "summary": "Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested- Favorable safety profile, with no safety concerns- Data will support...",
    "url": "https://finnhub.io/api/news?id=7742504afc436e8cafbee403ff6df1cebbc0be468f25a8399602ce15612a32e6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742195104,
      "headline": "Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa",
      "id": 133206143,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested- Favorable safety profile, with no safety concerns- Data will support...",
      "url": "https://finnhub.io/api/news?id=7742504afc436e8cafbee403ff6df1cebbc0be468f25a8399602ce15612a32e6"
    }
  }
]